Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Explore this paper's citation graph
Summary
The combination of bevacizumab with interferon alfa as first-line treatment in patients with metastatic renal cell carcinoma results in a significant improvement in progression-free survival, compared with InterferonAlfa alone.
- Type
- article
- Published
- 2007-12-22
- Cited by
- 2,274
- References
- 44
- OpenAlex
- https://openalex.org/W2100669312
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:9720977
Keywords
Medicine, Bevacizumab, Interim analysis, Clinical endpoint, Renal cell carcinoma
References
- Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients
- Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
- Cancer : Principles and Practice of Oncology
- Immunotherapy for advanced renal cell cancer.
- [New guidelines to evaluate the response to treatment in solid tumors].
- Cancer: Principles and Practice of Oncology
- Renal cancer: molecular mechanisms and newer therapeutic options
- Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
- Bevacizumab for Patients with Metastatic Renal Cancer
- Sorafenib in advanced clear-cell renal-cell carcinoma.
- The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis
- Treatment for renal cancer: are we beyond the cytokine era?
- Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
- Interim analysis: the alpha spending function approach.
- Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
- Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors
- Sunitinib in patients with metastatic renal cell carcinoma.
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
- Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Cited by
- Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy
- Compounds in clinical Phase III and beyond.
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
- Chemotherapie des Harnblasenkarzinoms
- Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
- Update on systemic therapies of metastatic renal cell carcinoma
- Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX‐specific chimeric monoclonal antibody cG250
- Past, present and future of targeted therapy in solid tumors.
- INTRAVITREAL BEVACIZUMAB DURING PREGNANCY
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
- Pancreatic metastases from renal cell carcinoma: the state of the art.
- Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
- Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
- Differential microRNA expression in renal cell carcinoma
- Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)
- Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies
- Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF‐directed Therapy
- AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma
- Immunotherapy in the Elderly.
Related papers
- Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice.
- A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
- Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil.
- Therapy of hepatitis C: Interferon alfa‐n1 trials
- Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
- Serum concentration of interferon-alpha: a comparison between once-a-day and twice-a-day administration.
- The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
- Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis
- Hemangioma gigante tratado com Interferon Alfa-2a Giant hemangioma treated with interferon alpha-2a
- Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).